Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616331 | 0.88 | LMNA (0.48) | KMT2APKMRAD52LMNASMN1; SMN2 | |
| SCHEMBL1377654 | 0.80 | LMNA (0.46) | PKMLMNASMN1; SMN2HTR6HTR2A | |
| SCHEMBL3618341 | 0.77 | RAD52 (0.64) | BRD4POLBKMT2APKMRAD52 | |
| Hydrochloric Acid SCHEMBL3619845 | 0.76 | RAD52 (0.65) | BRD4POLBKMT2APKMRAD52 | |
| SCHEMBL3621908 | 0.74 | RAD52 (0.60) | BRD4POLBKMT2APKMRAD52 | |
| SCHEMBL3626233 | 0.72 | HTR6 (0.52) | BRD4KMT2ARAD52LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1381800 | 0.72 | HTR6 (0.51) | BRD4KMT2ARAD52LMNASMN1; SMN2 | |
| SCHEMBL1379202 | 0.71 | HTR6 (0.45) | KMT2APKMLMNASMN1; SMN2HTR6 | |
| Hydrochloric Acid SCHEMBL3617007 | 0.71 | RAD52 (0.59) | BRD4POLBKMT2APKMRAD52 | |
| SCHEMBL27513811 | 0.71 | HTR6 (0.69) | BRD4POLBKMT2APKMRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | BRD4 2761/4885POLB 4287/4885KMT2A 2359/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | BRD4 2904/4885POLB 4217/4885KMT2A 1776/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | BRD4 301/4885POLB 3763/4885KMT2A 1435/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | BRD4 2904/4885POLB 4217/4885KMT2A 1776/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | BRD4 2761/4885POLB 4287/4885KMT2A 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.